YOLFTbeta
Abivax SA American Depositary Shares

Abivax SA American Depositary Shares

ABVX · NASDAQ · Healthcare / Biotechnology

87.58USD-2.62 (-2.90%)

Price History

Full chart

Market Stats

Previous Close90.20
Open90.00
Day Range86.25 – 90.00
52-Week Range69.81 – 148.83
Volume587.83K
Market Cap7.95B
P/E (TTM)0.00
Forward P/E0.00
EPS-6.10
Dividend Yield0.00%
Beta-0.25
50-Day Avg118.77
200-Day Avg118.68

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Marc M. P. de Garidel M.B.A.
  • Employees98
  • Headquarters7-11 Boulevard Haussmann, Paris, France, 75009, USA
  • Websitehttps://www.abivax.com

Leadership

  • Mr. Marc M. P. de Garidel M.B.A.CEO & Director · b. 1958
  • Mr. Didier BlondelEVP, CFO & Board Secretary · b. 1964
  • Dr. David Zhang Ph.D.Chief Strategy Officer · b. 1968
  • Dr. Keith M. Fournier Ph.D.Senior Vice President of Global Regulatory Affairs
  • Mr. Michael Nesrallah M.B.A.Chief Commercial Officer
  • Dr. Maurus de la Rosa Ph.D.Senior Vice President of Research
  • Mr. Ivan Nunez-PachecoGlobal Head of Patient Services
  • Ms. Heather DeanGlobal Head of Sales, Accounts & Commercial Operations
  • Mr. Jeffrey N. HaasGlobal Head of Market Access & Pricing

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue73.94K14.00K42.00K127.00K10.00K18.00K2.00K63.00K37.00K4.58M4.62M10.79M0
Growth (%)--81.07%+200.00%+202.38%-92.13%+80.00%-88.89%+3050.00%-41.27%+12286.49%+0.83%+133.54%-100.00%
Cost of Revenue5.63M3.28M345.00K14.64M14.51M15.38M28.19M33.78M45.52M50.76M707.00K-1.03M
Gross Profit-5.56M-3.27M-303.00K-14.52M-14.50M-15.36M-28.19M-33.78M-45.52M-50.76M4.57M10.79M-1.03M
Gross Margin-7516.07%-23321.43%-721.43%-11431.50%-144970.00%-85327.78%-1409300.00%-53623.81%-123018.92%-1107.66%98.98%100.00%-
Operating Expense1.84M1.79M17.95M3.72M-347.00K3.75M5.11M4.22M-4.12M14.07M131.95M183.78M245.03M
Operating Income-7.40M-5.05M-18.25M-18.24M-14.15M-19.11M-33.30M-38.01M-41.40M-64.84M-127.38M-172.98M-246.06M
Operating Margin-10003.64%-36100.00%-43464.29%-14359.06%-141500.00%-106155.56%-1664800.00%-60330.16%-111891.89%-1414.71%-2756.46%-1602.89%-
EBITDA-7.37M-4.97M-18.05M-17.86M-13.98M-19.23M-33.22M-38.00M-38.59M-53.31M-133.21M-162.71M-300.70M
EBITDA Margin-9972.84%-35514.29%-42988.10%-14063.78%-139800.00%-106816.67%-1661100.00%-60315.87%-104302.70%-1163.32%-2882.64%-1507.70%-
Net Income-5.89M-5.08M-15.95M-14.31M-11.22M-15.82M-30.63M-37.55M-42.45M-60.74M-147.74M-176.24M-336.10M
Net Income Margin-7970.18%-36285.71%-37985.71%-11266.14%-112230.00%-87905.56%-1531700.00%-59604.76%-114735.14%-1325.33%-3197.14%-1633.08%-
R&D--15.27M15.46M10.85M15.89M29.01M34.53M47.78M48.30M103.18M146.53M177.76M
R&D as % of Total Revenue--36350.00%12172.44%108460.00%88300.00%1450350.00%54803.17%129137.84%1053.79%2232.76%1357.78%-
Interest Expense168.93K65.00K168.00K42.00K31.00K469.00K1.59M2.06M3.56M6.94M13.83M12.43M28.48M
Interest Expense % of Total Revenue228.45%464.29%400.00%33.07%310.00%2605.56%79300.00%3273.02%9616.22%151.43%299.20%115.19%-

Balance Sheet

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.46M37.97M76.27M60.60M53.81M54.05M51.73M71.30M109.23M75.54M327.06M205.23M584.09M
Total Liabilities4.44M4.03M4.50M3.88M5.63M19.39M33.14M53.40M83.30M68.36M131.05M164.64M129.08M
Total Equity34.02M33.94M71.77M56.72M48.18M34.66M18.59M17.90M25.93M7.19M196.01M40.58M455.01M
Cash2.91M1.22M25.13M7.94M1.88M8.00M9.77M29.30M60.70M26.95M251.94M144.22M516.47M
Total Debt2.32M2.09M350.00K316.00K262.00K10.90M20.74M33.99M51.65M39.16M58.04M97.36M45.89M
Net Debt-587.71K868.96K-24.72M-7.62M-1.88M2.90M10.98M4.70M-9.05M12.21M-193.90M-46.86M-470.58M

Cash Flow

Currency: EUR2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.31M-14.90M-15.61M-8.45M-14.60M-27.47M-29.82M-45.05M-53.94M-100.01M-154.07M-155.69M
Investing Cash Flow-43.00K-1.02M-94.00K-105.00K-254.00K-370.00K-575.00K-6.23M-12.03M-10.49M15.76M-13.18M
Financing Cash Flow5.94M52.13M-438.00K2.60M10.83M24.61M49.93M82.68M32.21M340.57M28.21M531.94M
Capital Expenditure43.19K1.02M721.00K979.00K763.00K941.00K898.00K47.00K323.00K265.00K643.00K136.40K
Free Cash Flow-3.35M-15.93M-16.33M-9.43M-15.37M-28.41M-30.72M-45.09M-54.26M-100.28M-154.72M-155.83M
Dividends Paid-------00000
FCF to OCF101.31%106.88%104.62%111.59%105.22%103.43%103.01%100.10%100.60%100.27%100.42%100.09%
Dividend Paid to FCF-------0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateSep 21, 2023Nov 29, 2023Feb 6, 2024Apr 2, 2024Sep 9, 2024Nov 7, 2024Mar 24, 2025Jun 2, 2025Sep 8, 2025Dec 15, 2025Mar 23, 2026May 22, 2026Sep 21, 2026
EPS Estimate0.00-0.64-0.92-0.60-0.97-0.79-1.29-0.76-0.95-0.79-1.04-0.81-1.08
EPS Actual-0.72-0.640.00-0.79-1.01-0.72-0.81-0.95-0.89-2.47-1.18-0.71-1.71
Surprise-0.00%100.00%-31.72%-4.12%8.86%36.88%-25.00%6.32%-212.66%-13.46%12.35%-58.33%
Timing--After-hoursPre-market---After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap7.95B
Enterprise Value7.90B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1702.08
Price / Book19.54
EPS-6.10
Book Value5.22
Revenue (TTM)4.67M
Gross Profit (TTM)4.67M
EBITDA-291.55M
Profit Margin0.00%
Operating Margin-8617.93%
Return on Equity-252.35%
Return on Assets-62.88%
Shares Outstanding87.25M
Shares Float69.03M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 164.00
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
71.55%
Insiders
0.00%
Retail / Other
28.45%

Top Institutional Holders

  • TCG Crossover Management, LLC
    6.01M6.89%
  • UBS Group AG
    4.55M5.21%
  • Darwin Global Management, Ltd.
    3.62M4.15%
  • Helikon Investments Ltd
    2.79M3.19%
  • Morgan Stanley - Brokerage Accounts
    1.70M1.95%
  • Caligan Partners LP
    1.56M1.79%
  • Vestal Point Capital LP
    1.50M1.72%
  • Citadel Advisors Llc
    1.44M1.65%
  • ADAR1 Capital Management LLC
    1.39M1.60%
  • Westfield Capital Management Company, L.P.
    1.31M1.50%
  • FMR Inc
    1.29M1.47%
  • NORGES BANK
    1.10M1.26%
  • Logos Global Management LP
    1.02M1.17%
  • Octagon Capital Advisors LP
    993.00K1.14%
  • Eversept Partners, LP
    913.88K1.05%
  • HHG PLC
    878.83K1.01%
  • Baker Bros Advisors LP
    875.80K1.00%
  • Lord, Abbett & Co LLC
    854.92K0.98%
  • Cormorant Asset Management, LLC
    760.00K0.87%

Top Fund Holders

  • Xtrackers MSCI World Swap ETF 1C
    760.11K0.87%